期刊
EXPERT REVIEW OF PROTEOMICS
卷 14, 期 11, 页码 1007-1020出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14789450.2017.1384697
关键词
Mass spectrometry; cerebrospinal fluid; Alzheimer's disease; proteomics; immunoassays; biomarker
资金
- Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences
- Knut and Alice Wallenberg Foundation
- European Research Council
- Swedish Research Council
- Swedish Brain Foundation
- Swedish Alzheimer foundation
- Gun and Bertil Stohne's Foundation
- Demensforbundet
- Gamla Tjanarinnor's Foundation
- Ahlen-stiftelsen
- Frimurarestiftelsen
- Wallstroms och Sjobloms stiftelse
- Swedish federal government under the ALF
Introduction: Alzheimer's disease (AD) is a neurodegenerative disease affecting the brain. Today there are three cerebrospinal fluid (CSF) biomarkers, amyloid-beta consisting of 42 amino acids (A beta 42), total-tau (t-tau) and phosphorylated-tau (p-tau), which combined have sensitivity and specificity figures around 80%. However, pathological studies have shown that comorbidity is a common feature in AD and that the three currently used CSF biomarkers do not optimally reflect the activity of the disease process. Thus, additional markers are needed. Areas covered: In the present review, we screened PubMed for articles published the last five years (2012-2017) for proteomic studies in CSF with the criteria that AD had to be included as one of the diagnostic groups. Based on inclusion criteria, 28 papers were included reporting in total 224 biomarker- data that were altered in AD compared to control. Both mass spectrometry and multi-panel immunoassays were considered as proteomic studies. Expert commentary: A large number of pilot studies have been reported but so far there is a lack of replicated findings and to date no CSF biomarker discovered in proteomic studies has reached the clinic to aid in the diagnostic work-up of patients with cognitive impairment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据